Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Previously Published Works bannerUC San Diego

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

  • Author(s): Soulie, Cathia
  • Descamps, Diane
  • Grudé, Maxime
  • Schneider, Véronique
  • Trabaud, Mary-Anne
  • Morand-Joubert, Laurence
  • Delaugerre, Constance
  • Montes, Brigitte
  • Barin, Francis
  • Ferre, Virginie
  • Raymond, Stéphanie
  • Jeulin, Hélène
  • Alloui, Chakib
  • Yerly, Sabine
  • Pallier, Coralie
  • Reigadas, Sandrine
  • Signori-Schmuck, Anne
  • Guigon, Aurélie
  • Fafi-Kremer, Samira
  • Haïm-Boukobza, Stéphanie
  • Mirand, Audrey
  • Maillard, Anne
  • Vallet, Sophie
  • Roussel, Catherine
  • Assoumou, Lambert
  • Calvez, Vincent
  • Flandre, Philippe
  • Marcelin, Anne-Geneviève
  • ANRS Resistance AC11 Group
  • et al.

Published Web Location

https://academic.oup.com/jac/article/70/2/566/2911334
No data is associated with this publication.
Abstract

OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item